Does not explain cutting expenditure if they expect CE approval. Preserving cash seems the priority. If no CE and further trials where does the funding for US trial come from.
Does not explain cutting expenditure if they expect CE approval....
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
-0.015(1.25%) |
Mkt cap ! $17.20M | |||
| Open | High | Low | Value | Volume |
| $1.24 | $1.24 | $1.19 | $43.44K | 36.31K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5443 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 1651 | 1 |
View Market Depth
| Last trade - 10.58am 01/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |